Psychedelic research should do more to include indigenous knowledge systems
A commentary in the Journal of Psychopharmacology calls for indigenous communities to take an equal part in psychedelic research, governance and policy decisions.
Topic - drug policy
Australia as a pioneer in the medical use of psilocybin and MDMA
A review in the British Journal of Pharmacology examines Australia's regulated medical use of psilocybin and MDMA and its international significance.
The logic of drug policy: why are some stimulants accepted and others banned?
A conceptual paper asks why caffeine, nicotine and prescription stimulants are accepted while other psychoactive plants and compounds are criminalized.
New rule: statutory health insurers no longer pay for cannabis flowers
Since 30 July 2026, cannabis flowers are no longer covered by Germany's statutory health insurers; extracts, dronabinol and nabilone remain available.
Naturalistic psychedelic use from a public health perspective
A review of 104 peer-reviewed articles examines the mental, physical, and social effects of psychedelic use outside clinical settings.
Metabolomics improves the forensic detection of synthetic cathinones
A review examines how metabolomic methods can improve the forensic analysis of synthetic cathinones and support toxicology and public health.
Review: fly agaric is gaining relevance in the landscape of new psychoactive substances
A narrative review finds fly agaric increasingly marketed like a new psychoactive substance, with known risks and no treatment guidelines.
1Bz-LSD and 1-TMSBz-LSD: first detection of novel LSD derivatives in Japan
Researchers in Japan report the first detection of two new LSD analogues, 1Bz-LSD in tablets and 1-TMSBz-LSD on paper blotters.
Cannabis: legalization does not necessarily lead to higher use
A review of cannabis policy from 2000 to 2025 finds that decriminalization and tightly regulated legalization do not automatically raise consumption.
A guide to setting up psychedelic studies
A new review gathers the experience of leading British research groups into practical guidance for planning studies with psychedelic substances.
What Does Germany Need for Psychedelic-Assisted Therapy?
Framework Conditions for Psychedelic-Assisted Therapy in the German Healthcare SystemConsiderations on Access, Regulation, and Training in Psychedelic-Assisted Therapy Image 1: Sergio R. Pérez Rosal presents his poster...
No articles found
Try a different spelling or clear the filters.
Newsletter - Subscribe to our newsletter to get insights into current projects and events.
Stay connected with a community that fosters a responsible and forward-thinking dialogue on psychedelic experience – and receive news about projects, events, and publications.
By subscribing, you agree to our Privacy Policy.